Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus PROPANTHELINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus PROPANTHELINE BROMIDE.
LUSEDRA vs PROPANTHELINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Antimuscarinic; competitively blocks acetylcholine at postganglionic muscarinic receptors, inhibiting parasympathetic nerve impulses.
5 mg orally once daily.
15 mg orally 3 times daily before meals and 30 mg at bedtime; initial dose may be 15 mg 3 times daily.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal half-life 2.5-4 hours; clinically, dosing every 6 hours maintains therapeutic levels.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Approximately 70% renal (tubular secretion) as metabolites and unchanged drug; 30% biliary/fecal.
Category C
Category A/B
Anticholinergic
Anticholinergic